{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:39:58Z","timestamp":1792593598026,"version":"4.5.0"},"reference-count":34,"publisher":"MyJove Corporation","issue":"227","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/69725","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:35Z","timestamp":1769212835000},"source":"Crossref","is-referenced-by-count":0,"title":["Antiproliferative Plaque Assay for Screening <em>in vitro<\/em> Bioactive Molecules against <em>Toxoplasma gondii<\/em> Tachyzoites"],"prefix":"10.3791","author":[{"given":"Mike dos","family":"Santos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9ia Luiza Oliveira","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana Maciel","family":"Cunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adalberto Alves","family":"Pereira Filho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Wagner","family":"de Almeida Vitor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9rica S.","family":"Martins-Duarte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"issue":"4","key":"ref1","first-page":"898","type":"journal-article","article-title":"Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots","volume":"36","author":"Molan","year":"2019","unstructured":"Molan A., Nosaka, K., Hunter, M., Wang, W. Global status of Toxoplasma gondii infection: systematic review and prevalence snapshots. Trop Biomed. 36 (4), 898-925 (2019).","journal-title":"Trop Biomed"},{"issue":"1","key":"ref2","doi-asserted-by":"crossref","first-page":"12102","DOI":"10.1038\/s41598-020-69078-9","type":"journal-article","article-title":"Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: A systematic review, modelling and meta-analysis","volume":"10","author":"Bigna","year":"2020","unstructured":"Bigna, J. J. et al. Global, regional, and country seroprevalence of Toxoplasma gondii in pregnant women: A systematic review, modelling and meta-analysis. Sci Rep. 10 (1), 12102 (2020).","journal-title":"Sci Rep"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/20477724.2022.2083977","type":"journal-article","article-title":"Cerebral toxoplasmosis in HIV-infected patients: A review","volume":"117","author":"Dian","year":"2023","unstructured":"Dian, S., Ganiem, A. R., Ekawardhani, S. Cerebral toxoplasmosis in HIV-infected patients: A review. Pathog Glob Health. 117 (1), 14-23 (2023).","journal-title":"Pathog Glob Health"},{"key":"ref4","first-page":"389","type":"journal-article","article-title":"Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis","volume":"8","author":"Wang","year":"2017","unstructured":"Wang, Z.-D. et al. Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis. Front Microbiol. 8, 389 (2017).","journal-title":"Front Microbiol"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3390\/pathogens12040543","type":"journal-article","article-title":"Clinical spectrum, radiological findings, and outcomes of severe toxoplasmosis in immunocompetent hosts: A systematic review","volume":"12","author":"Layton","year":"2023","unstructured":"Layton, J. et al. Clinical spectrum, radiological findings, and outcomes of severe toxoplasmosis in immunocompetent hosts: A systematic review. Pathogens. 12 (4), 543 (2023).","journal-title":"Pathogens"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.ijpara.2009.02.004","type":"journal-article","article-title":"Toxoplasmosis: A history of clinical observations","volume":"39","author":"Weiss","year":"2009","unstructured":"Weiss, L. M., Dubey, Jitender. P. Toxoplasmosis: A history of clinical observations. Int J Parasitology. 39 (8), 895-901 (2009).","journal-title":"Int J Parasitology"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"106180","DOI":"10.1016\/j.actatropica.2021.106180","type":"journal-article","article-title":"Ocular toxoplasmosis, an overview focusing on clinical aspects","volume":"225","author":"Fabiani","year":"2022","unstructured":"Fabiani, S. et al. Ocular toxoplasmosis, an overview focusing on clinical aspects. Acta Trop. 225, 106180 (2022).","journal-title":"Acta Trop"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1442-9071.2012.02838.x","type":"journal-article","article-title":"Ocular toxoplasmosis II: Clinical features, pathology and management","volume":"41","author":"Butler","year":"2013","unstructured":"Butler, N. J., Furtado, J. M., Winthrop, K. L., Smith, J. R. Ocular toxoplasmosis II: Clinical features, pathology and management. Clin Exp Ophthalmol. 41 (1), 95-108 (2013).","journal-title":"Clin Exp Ophthalmol"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"e00057","DOI":"10.1128\/CMR.00057-17","type":"journal-article","article-title":"Treatment of Toxoplasmosis: Historical perspective, animal models, and current clinical practice","volume":"31","author":"Dunay","year":"2018","unstructured":"Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., Montoya, J. G. Treatment of Toxoplasmosis: Historical perspective, animal models, and current clinical practice. Clin Microbiol Rev. 31 (4), e00057-17 (2018).","journal-title":"Clin Microbiol Rev"},{"issue":"9","key":"ref10","doi-asserted-by":"crossref","first-page":"e0138204","DOI":"10.1371\/journal.pone.0138204","type":"journal-article","article-title":"A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans","volume":"10","author":"Wei","year":"2015","unstructured":"Wei, H.-X., Wei, S.-S., Lindsay, D. S., Peng, H.-J. A systematic review and meta-analysis of the efficacy of anti-Toxoplasma gondii medicines in humans. PloS One. 10 (9), e0138204 (2015).","journal-title":"PloS One"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1038\/s41598-020-80569-7","type":"journal-article","article-title":"Adverse outcomes associated with the treatment of Toxoplasma infections","volume":"11","author":"Shammaa","year":"2021","unstructured":"Shammaa, A. M., Powell, T. G., Benmerzouga, I. Adverse outcomes associated with the treatment of Toxoplasma infections. Sci Rep. 11 (1), 1035, (2021).","journal-title":"Sci Rep"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/nbt.2786","type":"journal-article","article-title":"Clinical development success rates for investigational drugs","volume":"32","author":"Hay","year":"2014","unstructured":"Hay, M., Thomas, D.W., Craighead, J. L., Economides, C., Rosenthal, J. Clinical development success rates for investigational drugs. Nat Biotechnol. 32 (1), 40-51 (2014).","journal-title":"Nat Biotechnol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","type":"journal-article","article-title":"How to improve R&D productivity: The pharmaceutical industry's grand challenge","volume":"9","author":"Paul","year":"2010","unstructured":"Paul, S. M. et al. How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 9 (3), 203-214 (2010).","journal-title":"Nat Rev Drug Discov"},{"issue":"11","key":"ref14","doi-asserted-by":"crossref","first-page":"e5644","DOI":"10.1590\/1414-431x20165644","type":"journal-article","article-title":"Non-clinical studies required for new drug development - Part I: Early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies","volume":"49","author":"Andrade","year":"2016","unstructured":"Andrade, E. L. et al. Non-clinical studies required for new drug development - Part I: Early in silico and in vitro studies, new target discovery and validation, proof of principles and robustness of animal studies. Braz J Med Biol Res. 49 (11), e5644 (2016).","journal-title":"Braz J Med Biol Res"},{"issue":"6","key":"ref15","first-page":"578","type":"journal-article","article-title":"Preclinical drug development","volume":"67","author":"Brodniewicz","year":"2010","unstructured":"Brodniewicz, T., Grynkiewicz, G. Preclinical drug development. Acta Poloniae Pharmaceutica. 67 (6), 578-585 (2010).","journal-title":"Acta Poloniae Pharmaceutica"},{"issue":"8","key":"ref16","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1073\/pnas.38.8.747","type":"journal-article","article-title":"Production of plaques in monolayer tissue cultures by single particles of an animal virus","volume":"38","author":"Dulbecco","year":"1952","unstructured":"Dulbecco, R. Production of plaques in monolayer tissue cultures by single particles of an animal virus. Proc Natl Acad Sci U S A. 38 (8), 747-752 (1952).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref17","doi-asserted-by":"crossref","first-page":"470","DOI":"10.2307\/3225139","type":"journal-article","article-title":"The use of the plaque assay in chemotherapeutic and dermal hypersensitivity studies on Toxoplasma gondii","volume":"95","author":"Roberts","year":"1976","unstructured":"Roberts, C. O., Chaparas, S. D., McLaughlin, D. The use of the plaque assay in chemotherapeutic and dermal hypersensitivity studies on Toxoplasma gondii. Trans Am Microsc Soc. 95 (3), 470 (1976).","journal-title":"Trans Am Microsc Soc"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ijpddr.2023.02.001","type":"journal-article","article-title":"Effect of the Pseudomonas metabolites HQNO on the Toxoplasma gondii RH strain in vitro and in vivo","volume":"21","author":"Mo","year":"2023","unstructured":"Mo, J. et al. Effect of the Pseudomonas metabolites HQNO on the Toxoplasma gondii RH strain in vitro and in vivo. Int J Parasitol Drugs Drug Resist. 21, 74-80 (2023).","journal-title":"Int J Parasitol Drugs Drug Resist"},{"issue":"1-2","key":"ref19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.vetpar.2011.12.039","type":"journal-article","article-title":"Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models","volume":"187","author":"Barbosa","year":"2012","unstructured":"Barbosa, B. F. et al. Enrofloxacin is able to control Toxoplasma gondii infection in both in vitro and in vivo experimental models. Vet Parasitol. 187 (1-2), 44-52 (2012).","journal-title":"Vet Parasitol"},{"issue":"9","key":"ref20","doi-asserted-by":"crossref","first-page":"e00924","DOI":"10.1128\/AAC.00924-20","type":"journal-article","article-title":"Screening repurposing libraries for identification of drugs with novel antifungal activity","volume":"64","author":"Wall","year":"2020","unstructured":"Wall, G., Lopez-Ribot, J. L. Screening repurposing libraries for identification of drugs with novel antifungal activity. Antimicrob Agents Chemother. 64 (9), e00924-20 (2020).","journal-title":"Antimicrob Agents Chemother"},{"issue":"12","key":"ref21","doi-asserted-by":"crossref","DOI":"10.3390\/tropicalmed8120510","type":"journal-article","article-title":"Medicines for malaria venture pandemic box in vitro screening identifies compounds highly active against the tachyzoite stage of Toxoplasma gondii","volume":"8","author":"dos Santos","year":"2023","unstructured":"dos Santos, M. et al. Medicines for malaria venture pandemic box in vitro screening identifies compounds highly active against the tachyzoite stage of Toxoplasma gondii. Trop Med Infect Dis. 8 (12) (2023).","journal-title":"Trop Med Infect Dis"},{"issue":"12","key":"ref22","doi-asserted-by":"crossref","first-page":"2602","DOI":"10.3390\/microorganisms12122602","type":"journal-article","article-title":"Antiproliferative and morphological analysis triggered by drugs contained in the medicines for malaria venture COVID-box against Toxoplasma gondii tachyzoites","volume":"12","author":"Costa","year":"2024","unstructured":"Costa, A.L.O. et al. Antiproliferative and morphological analysis triggered by drugs contained in the medicines for malaria venture COVID-box against Toxoplasma gondii tachyzoites. Microorganisms. 12 (12), 2602 (2024).","journal-title":"Microorganisms"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.exppara.2016.12.015","type":"journal-article","article-title":"Toxoplasma gondii plaque assays revisited: Improvements for ultrastructural and quantitative evaluation of lytic parasite growth","volume":"180","author":"Ufermann","year":"2017","unstructured":"Ufermann, C.-M., M\u00fcller, F., Frohnecke, N., Laue, M., Seeber, F. Toxoplasma gondii plaque assays revisited: Improvements for ultrastructural and quantitative evaluation of lytic parasite growth. Exp Parasitol. 180, 19-26 (2017).","journal-title":"Exp Parasitol"},{"key":"ref24","first-page":"25","type":"journal-article","article-title":"Principles of virology","volume":"I","author":"Condit","year":"2007","unstructured":"Condit, R. C. Principles of virology. In Fields Virology. Vol. I, 25-57 (2007).","journal-title":"Fields Virology"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.exppara.2019.03.009","type":"journal-article","article-title":"In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis","volume":"200","author":"Montazeri","year":"2019","unstructured":"Montazeri, M. et al. In vitro and in vivo evaluation of kojic acid against Toxoplasma gondii in experimental models of acute toxoplasmosis. Exp Parasitol. 200, 7-12 (2019).","journal-title":"Exp Parasitol"},{"issue":"10","key":"ref26","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1128\/AAC.34.10.1961","type":"journal-article","article-title":"Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives","volume":"34","author":"Ke","year":"1990","unstructured":"Ke, O. Y., Krug, E. C., Marr, J. J., Berens, R. L. Inhibition of growth of Toxoplasma gondii by qinghaosu and derivatives. Antimicrob Agents Chemother. 34 (10), 1961-1965 (1990).","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.3390\/toxins15080477","type":"journal-article","article-title":"Anti-Toxoplasma gondii effects of lipopeptide derivatives of Lycosin-I","volume":"15","author":"Liu","year":"2023","unstructured":"Liu, X. et al. Anti-Toxoplasma gondii effects of lipopeptide derivatives of Lycosin-I. Toxins. 15 (8), 477 (2023).","journal-title":"Toxins"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"12429","DOI":"10.1038\/s41598-025-97590-3","type":"journal-article","article-title":"Development of an automated plaque-counting program for the quantification of the Chikungunya virus","volume":"15","author":"Emi","year":"2025","unstructured":"Emi, A. et al. Development of an automated plaque-counting program for the quantification of the Chikungunya virus. Sci Rep. 15 (1), 12429 (2025).","journal-title":"Sci Rep"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.jviromet.2011.10.003","type":"journal-article","article-title":"High throughput virus plaque quantitation using a flatbed scanner","volume":"179","author":"Sullivan","year":"2012","unstructured":"Sullivan, K. et al. High throughput virus plaque quantitation using a flatbed scanner. J Virol Methods. 179 (1), 81-89 (2012).","journal-title":"J Virol Methods"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3390\/metabo13010095","type":"journal-article","article-title":"In vitro activity of essential oils from piper species (Piperaceae) against tachyzoites of Toxoplasma gondii","volume":"13","author":"Pereira Filho","year":"2023","unstructured":"Pereira Filho, A. A. et al. In vitro activity of essential oils from piper species (Piperaceae) against tachyzoites of Toxoplasma gondii. Metabolites. 13 (1), 95 (2023).","journal-title":"Metabolites"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"116467","DOI":"10.1016\/j.bmc.2021.116467","type":"journal-article","article-title":"In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii","volume":"50","author":"Martins-Duarte","year":"2021","unstructured":"Martins-Duarte, E.S. et al. In vitro activity of N-phenyl-1,10-phenanthroline-2-amines against tachyzoites and bradyzoites of Toxoplasma gondii. Bioorg Medl Chem. 50, 116467 (2021).","journal-title":"Bioorg Medl Chem"},{"issue":"7","key":"ref32","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","type":"journal-article","article-title":"NIH Image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S., Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods. 9 (7), 671-675 (2012).","journal-title":"Nat Methods"},{"issue":"1","key":"ref33","doi-asserted-by":"crossref","first-page":"e00534","DOI":"10.1128\/mSphere.00534-17","type":"journal-article","article-title":"Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box molecules","volume":"3","author":"Subramanian","year":"2018","unstructured":"Subramanian, G. et al. Targeted phenotypic screening in Plasmodium falciparum and Toxoplasma gondii reveals novel modes of action of medicines for malaria venture malaria box molecules. mSphere. 3 (1), e00534-17 (2018).","journal-title":"mSphere"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.ijpara.2020.01.002","type":"journal-article","article-title":"Screening the medicines for malaria venture pathogen box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds","volume":"50","author":"Dans","year":"2020","unstructured":"Dans, M. G. et al. Screening the medicines for malaria venture pathogen box for invasion and egress inhibitors of the blood stage of Plasmodium falciparum reveals several inhibitory compounds. Int J Parasitol. 50 (3), 235-252 (2020).","journal-title":"Int J Parasitol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/69725\/antiproliferative-plaque-assay-for-screening-vitro-bioactive","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:49:54Z","timestamp":1792590594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jove.com\/t\/69725\/antiproliferative-plaque-assay-for-screening-vitro-bioactive"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":34,"journal-issue":{"issue":"227","published-online":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.3791\/69725","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]}}}